Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Pilot study of a ketogenic diet in relapsing-remitting MS.

Brenton JN, Banwell B, Bergqvist AGC, Lehner-Gulotta D, Gampper L, Leytham E, Coleman R, Goldman MD.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 12;6(4):e565. doi: 10.1212/NXI.0000000000000565. eCollection 2019 Jul.

2.

The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis.

Brenton JN, Koshiya H, Woolbright E, Goldman MD.

Mult Scler J Exp Transl Clin. 2019 Apr 29;5(2):2055217319846141. doi: 10.1177/2055217319846141. eCollection 2019 Apr-Jun.

3.

Body mass index trajectories in pediatric multiple sclerosis.

Brenton JN, Woolbright E, Briscoe-Abath C, Qureshi A, Conaway M, Goldman MD.

Dev Med Child Neurol. 2019 Apr 5. doi: 10.1111/dmcn.14233. [Epub ahead of print]

PMID:
30950520
4.

Cost-Related Underuse of Medicines for Asthma-Opportunities for Improving Adherence.

Laba TL, Jan S, Zwar NA, Roughead E, Marks GB, Flynn AW, Goldman MD, Heaney A, Lembke KA, Reddel HK.

J Allergy Clin Immunol Pract. 2019 Mar 27. pii: S2213-2198(19)30305-8. doi: 10.1016/j.jaip.2019.03.024. [Epub ahead of print]

PMID:
30928659
5.

Cerebellar syndrome in a man treated with natalizumab: From the National Multiple Sclerosis Society Case Conference Proceedings.

Lapides DA, Batchala PP, Donahue JH, Lisak RP, Meltzer EI, Narayan RN, Nath A, Frohman TC, Costello K, Goldman MD, Zamvil SS, Frohman EM.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e546. doi: 10.1212/NXI.0000000000000546. eCollection 2019 May. No abstract available.

6.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

7.

Development of a gait module to complement the 12-item Multiple Sclerosis Walking Scale: a mixed methods study.

Strzok S, Cleanthous S, Pompilus F, Cano SJ, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY.

Mult Scler J Exp Transl Clin. 2018 Jun 26;4(2):2055217318783766. doi: 10.1177/2055217318783766. eCollection 2018 Apr-Jun.

8.

Addressing the targeting range of the ABILHAND-56 in relapsing-remitting multiple sclerosis: A mixed methods psychometric study.

Cleanthous S, Strzok S, Pompilus F, Cano S, Marquis P, Cohan S, Goldman MD, Kresa-Reahl K, Petrillo J, Castrillo-Viguera C, Cadavid D, Chen SY.

Mult Scler J Exp Transl Clin. 2018 May 17;4(2):2055217318776990. doi: 10.1177/2055217318776990. eCollection 2018 Apr-Jun.

9.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
10.

Understanding the Physiological Significance of Four Inertial Gait Features in Multiple Sclerosis.

Dandu SR, Engelhard MM, Qureshi A, Gong J, Lach JC, Brandt-Pearce M, Goldman MD.

IEEE J Biomed Health Inform. 2018 Jan;22(1):40-46. doi: 10.1109/JBHI.2017.2773629.

11.

Real-world walking in multiple sclerosis: Separating capacity from behavior.

Engelhard MM, Patek SD, Lach JC, Goldman MD.

Gait Posture. 2018 Jan;59:211-216. doi: 10.1016/j.gaitpost.2017.10.015. Epub 2017 Oct 16.

12.

Breastfeeding During Infancy Is Associated With a Lower Future Risk of Pediatric Multiple Sclerosis.

Brenton JN, Engel CE, Sohn MW, Goldman MD.

Pediatr Neurol. 2017 Dec;77:67-72. doi: 10.1016/j.pediatrneurol.2017.09.007. Epub 2017 Sep 14.

PMID:
29074058
13.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

14.

Glucocorticoid-associated blood glucose response and MS relapse recovery.

Goldman MD, Koenig S, Engel C, McCartney CR, Sohn MW.

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 18;4(5):e378. doi: 10.1212/NXI.0000000000000378. eCollection 2017 Sep.

15.

Helicobacter pylori Adapts to Chronic Infection and Gastric Disease via pH-Responsive BabA-Mediated Adherence.

Bugaytsova JA, Björnham O, Chernov YA, Gideonsson P, Henriksson S, Mendez M, Sjöström R, Mahdavi J, Shevtsova A, Ilver D, Moonens K, Quintana-Hayashi MP, Moskalenko R, Aisenbrey C, Bylund G, Schmidt A, Åberg A, Brännström K, Königer V, Vikström S, Rakhimova L, Hofer A, Ögren J, Liu H, Goldman MD, Whitmire JM, Ådén J, Younson J, Kelly CG, Gilman RH, Chowdhury A, Mukhopadhyay AK, Nair GB, Papadakos KS, Martinez-Gonzalez B, Sgouras DN, Engstrand L, Unemo M, Danielsson D, Suerbaum S, Oscarson S, Morozova-Roche LA, Olofsson A, Gröbner G, Holgersson J, Esberg A, Strömberg N, Landström M, Eldridge AM, Chromy BA, Hansen LM, Solnick JV, Lindén SK, Haas R, Dubois A, Merrell DS, Schedin S, Remaut H, Arnqvist A, Berg DE, Borén T.

Cell Host Microbe. 2017 Mar 8;21(3):376-389. doi: 10.1016/j.chom.2017.02.013.

16.

Relationship between gait variables and domains of neurologic dysfunction in multiple sclerosis using six-minute walk test.

Qureshi A, Brandt-Pearce M, Goldman MD.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:4959-4962. doi: 10.1109/EMBC.2016.7591840.

PMID:
28269381
17.

Remotely engaged: Lessons from remote monitoring in multiple sclerosis.

Engelhard MM, Patek SD, Sheridan K, Lach JC, Goldman MD.

Int J Med Inform. 2017 Apr;100:26-31. doi: 10.1016/j.ijmedinf.2017.01.006. Epub 2017 Jan 12.

18.

Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project.

Dickerson E, Davenport MS, Syed F, Stuve O, Cohen JA, Rinker JR, Goldman MD, Segal BM, Foerster BR; Michigan Radiology Quality Collaborative.

J Am Coll Radiol. 2017 Mar;14(3):371-379.e1. doi: 10.1016/j.jacr.2016.09.037. Epub 2016 Dec 5.

PMID:
27932248
19.

Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale.

Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D.

Mult Scler. 2017 Sep;23(10):1405-1414. doi: 10.1177/1352458516680749. Epub 2016 Dec 7.

20.

Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.

Ward MD, Jones DE, Goldman MD.

Mult Scler Relat Disord. 2016 Sep;9:47-9. doi: 10.1016/j.msard.2016.06.007. Epub 2016 Jun 23.

PMID:
27645342
21.

Fatigue and fluid hydration status in multiple sclerosis: A hypothesis.

Cincotta MC, Engelhard MM, Stankey M, Goldman MD.

Mult Scler. 2016 Oct;22(11):1438-1443. Epub 2016 Aug 19.

22.

Quantifying six-minute walk induced gait deterioration with inertial sensors in multiple sclerosis subjects.

Engelhard MM, Dandu SR, Patek SD, Lach JC, Goldman MD.

Gait Posture. 2016 Sep;49:340-345. doi: 10.1016/j.gaitpost.2016.07.184. Epub 2016 Jul 27.

23.

A study of dietary modification: Perceptions and attitudes of patients with multiple sclerosis.

Brenton JN, Goldman MD.

Mult Scler Relat Disord. 2016 Jul;8:54-7. doi: 10.1016/j.msard.2016.04.009. Epub 2016 Apr 27.

PMID:
27456874
24.

Causality Analysis of Inertial Body Sensors for Multiple Sclerosis Diagnostic Enhancement.

Gong J, Qi Y, Goldman MD, Lach J.

IEEE J Biomed Health Inform. 2016 Sep;20(5):1273-80. doi: 10.1109/JBHI.2016.2589902. Epub 2016 Jul 9.

PMID:
27411232
25.

The e-MSWS-12: improving the multiple sclerosis walking scale using item response theory.

Engelhard MM, Schmidt KM, Engel CE, Brenton JN, Patek SD, Goldman MD.

Qual Life Res. 2016 Dec;25(12):3221-3230. Epub 2016 Jun 24.

PMID:
27342237
26.

PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents.

Kanth KM, Solorzano GE, Goldman MD.

Neurol Clin Pract. 2016 Apr;6(2):e17-e19. No abstract available.

27.

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.

Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D.

Mult Scler. 2017 Jan;23(1):94-105. doi: 10.1177/1352458516638941. Epub 2016 Jul 11.

PMID:
27003945
28.

A Randomized Controlled Comparison of Esophageal Clearance Times of Oral Budesonide Preparations.

Hefner JN, Howard RS, Massey R, Valencia M, Stocker DJ, Philla KQ, Goldman MD, Nylund CM, Min SB.

Dig Dis Sci. 2016 Jun;61(6):1582-90. doi: 10.1007/s10620-015-3990-4. Epub 2016 Feb 26.

PMID:
26921083
29.

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ.

Clin Ther. 2015 Dec 1;37(12):2780-7. doi: 10.1016/j.clinthera.2015.10.014. Epub 2015 Nov 10.

30.

Smoking Beyond Multiple Sclerosis Diagnosis: A Risk Factor Still Worth Modifying.

Goldman MD, Stüve O.

JAMA Neurol. 2015 Oct;72(10):1105-6. doi: 10.1001/jamaneurol.2015.1805. No abstract available.

PMID:
26348489
31.

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR 3rd, Blight AR, Carrazana EJ.

Int J MS Care. 2015 May-Jun;17(3):138-45. doi: 10.7224/1537-2073.2014-040.

32.

Vitamin D status and age of onset of demyelinating disease.

Brenton JN, Koenig S, Goldman MD.

Mult Scler Relat Disord. 2014 Nov;3(6):684-8. doi: 10.1016/j.msard.2014.07.004. Epub 2014 Jul 28.

PMID:
25891547
33.

Analysis of a single Helicobacter pylori strain over a 10-year period in a primate model.

Liu H, Fero JB, Mendez M, Carpenter BM, Servetas SL, Rahman A, Goldman MD, Boren T, Salama NR, Merrell DS, Dubois A.

Int J Med Microbiol. 2015 May;305(3):392-403. doi: 10.1016/j.ijmm.2015.03.002. Epub 2015 Mar 6.

34.

Glottal Aperture and Buccal Airflow Leaks Critically Affect Forced Oscillometry Measurements.

Bikov A, Pride NB, Goldman MD, Hull JH, Horvath I, Barnes PJ, Usmani OS, Paredi P.

Chest. 2015 Sep;148(3):731-738. doi: 10.1378/chest.14-2644.

PMID:
25742459
35.

Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.

Goldman MD, Naismith RT.

Neurology. 2015 Mar 3;84(9):864-5. doi: 10.1212/WNL.0000000000001319. Epub 2015 Jan 30. No abstract available.

PMID:
25636716
36.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.

Jones DE, Goldman MD.

Expert Rev Clin Immunol. 2014 Oct;10(10):1281-91. doi: 10.1586/1744666X.2014.951332. Epub 2014 Aug 22. Review.

PMID:
25148422
37.

Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.

Ward MD, Jones DE, Goldman MD.

Expert Opin Drug Saf. 2014 Jul;13(7):989-98. doi: 10.1517/14740338.2014.920820. Review.

PMID:
24935480
38.

Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world.

Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D.

Neurology. 2013 Nov 19;81(21):1856-63. doi: 10.1212/01.wnl.0000436065.97642.d2. Epub 2013 Oct 30.

39.

Clinical importance of steps taken per day among persons with multiple sclerosis.

Motl RW, Pilutti LA, Learmonth YC, Goldman MD, Brown T.

PLoS One. 2013 Sep 4;8(9):e73247. doi: 10.1371/journal.pone.0073247. eCollection 2013.

40.

Thickened gastrointestinal wall findings on computed tomography in children: a reason for endoscopy?

Min SB, Nylund CM, Abbas MI, Carter M, Olsen CH, Biko DM, Goldman MD.

J Pediatr Gastroenterol Nutr. 2013 Sep;57(3):305-10. doi: 10.1097/MPG.0b013e3182952eaa.

PMID:
23575298
41.

Esophageal mucosal bridge in a 7-year-old.

Abbas MI, Wilson CC, Biko DM, Goldman MD.

J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):e1. doi: 10.1097/MPG.0b013e31825a22aa. No abstract available.

PMID:
22516865
42.

Evidence for the different physiological significance of the 6- and 2-minute walk tests in multiple sclerosis.

Motl RW, Suh Y, Balantrapu S, Sandroff BM, Sosnoff JJ, Pula J, Goldman MD, Fernhall B.

BMC Neurol. 2012 Mar 1;12:6. doi: 10.1186/1471-2377-12-6.

43.

Novel mathematical processing method of nocturnal oximetry for screening patients with suspected sleep apnoea syndrome.

Poupard L, Philippe C, Goldman MD, Sartène R, Mathieu M.

Sleep Breath. 2012 Jun;16(2):419-25. doi: 10.1007/s11325-011-0518-9. Epub 2011 Apr 15.

PMID:
21494850
44.

Analysis of impulse oscillometric measures of lung function and respiratory system model parameters in small airway-impaired and healthy children over a 2-year period.

Meraz EG, Nazeran H, Ramos CD, Nava P, Diong B, Goldman MD, Goldman CA.

Biomed Eng Online. 2011 Mar 25;10:21. doi: 10.1186/1475-925X-10-21. Erratum in: Biomed Eng Online. 2011;10:43. Goldman, Christine A [added].

45.

No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis.

Stüve O, Wang J, Chan A, Hemmer B, Cepok S, Nessler S, Zipp F, Goldman MD, Meuth SG, Korth C, Lambracht-Washington D.

Arch Neurol. 2011 Feb;68(2):264-5. doi: 10.1001/archneurol.2010.354. No abstract available. Erratum in: Arch Neurol. 2011 Mar;68(3):302.

PMID:
21320996
46.

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Goldman MD, Motl RW, Rudick RA.

Ther Adv Neurol Disord. 2010 Jul;3(4):229-39. doi: 10.1177/1756285610374117.

47.

Walking impairment in patients with multiple sclerosis: exercise training as a treatment option.

Motl RW, Goldman MD, Benedict RH.

Neuropsychiatr Dis Treat. 2010 Nov 16;6:767-74. doi: 10.2147/NDT.S10480.

48.

Electrical circuit models of the human respiratory system reflect small airway impairment measured by impulse oscillation (IOS).

Goldman MD, Nazeran H, Ramos C, Toon E, Oates K, Bilton D, Meraz E, Hafezi N, Diong B.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:2467-72. doi: 10.1109/IEMBS.2010.5626611.

PMID:
21096162
49.

Circuit analysis justifies a reduced Mead's model of the human respiratory impedance for impulse oscillometry data.

Ramos C, Nazeran H, Goldman MD, Diong B.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:548-52. doi: 10.1109/IEMBS.2010.5626522.

PMID:
21096096
50.

Real-life walking impairment in multiple sclerosis: preliminary comparison of four methods for processing accelerometry data.

Sosnoff JJ, Goldman MD, Motl RW.

Mult Scler. 2010 Jul;16(7):868-77. doi: 10.1177/1352458510373111. Epub 2010 Jun 9.

PMID:
20534642

Supplemental Content

Loading ...
Support Center